Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

26 dicembre 2021 Senza categoria
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
0 out of 5 based on 0 user ratings

Journal of Clinical Oncology, Ahead of Print.

Related Posts

Lascia un commento